Director Robert E. George filed a Form 4 with the SEC on November 19, 2026, disclosing the acquisition of stock options in Moleculin Biotech, Inc. (NASDAQ:MBRX) on November 17, 2026.

Key Highlights

  • Transaction date: November 17, 2026, with 4,000 stock options (right to buy) acquired by Director Robert E. George.
  • Exercise price: $6.83 per share, with an expiration date of November 17, 2036.
  • Vesting condition: Options vest on the earlier of November 17, 2027, or the date of the company's next annual meeting of shareholders, subject to continued Board service.
  • Post-transaction holdings: George beneficially owns 4,334 stock options following the reported transaction, held directly.
  • Purpose: According to the filing, the options were issued in connection with the reporting person's Board of Director service to the company.

Moleculin Biotech Director Receives Board Retainer Options in November 2026

According to the Form 4 filed on November 19, 2026, Robert E. George, a director of Moleculin Biotech, Inc., acquired 4,000 stock options with the right to buy common stock at an exercise price of $6.83 per share. The transaction was dated November 17, 2026, and the options carry an expiration date of November 17, 2036. The filing was submitted by Jonathan Foster by Power of Attorney on behalf of George.

The filing states that the options vest on the earlier of November 17, 2027, or the date of the company's next annual meeting of shareholders, "subject to the grantee's continued service on the Company's Board of Directors on the vesting date." The options were described as issued in connection with the reporting person's Board of Director service to the company. No shares of non-derivative common stock were listed in Table I of the filing.

Following the reported transaction, George beneficially owns 4,334 stock options in total, held directly, according to the filing. The Form 4 was filed by one reporting person and indicates George's relationship to the issuer solely as a director, with no 10% ownership or officer title noted.

What Was Disclosed

Moleculin Biotech director Robert E. George disclosed the acquisition of 4,000 stock options at an exercise price of $6.83, issued for Board service, with vesting tied to November 2027 or the next annual shareholder meeting, and a 2036 expiration date.